Global ESG Clever Leaves is a multinational cannabinoid API and finished product producer with a focus on environmentally sustainable, low-cost production and strong pharmaceutical-quality certifications, signaling a readiness to partner with global customers seeking compliant, ESG-aligned supply.

Strategic Partnerships Recent partnerships and restructuring moves, including a collaboration with Australian Natural Therapeutics Group and a shift of operations to Colombia, indicate openness to new distribution channels and cross-regional market access for medical cannabis products.

Market Expansion Expansion of offices and facilities in multiple regions, plus a move away from Portugal toward Colombia, suggests a heavy emphasis on scalable, geographically diversified supply to meet growing B2B demand.

B2B Focus Operations centered on producing cannabinoid APIs and finished products for global B2B customers position Clever Leaves as a potential supplier for pharmaceutical manufacturers, compounding pharmacies, and regional distributors seeking compliant cannabis-derived ingredients.

Automation & Compliance With a pharmaceutical-grade production approach and a track record of certifications, there is a sales opportunity to pitch end-to-end GMP-like quality, audits, and documentation support to potential pharma and regulated partners seeking reliable cannabis-derived components.